Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

BACKGROUND: Nivolumab with ipilimumab (the Regimen) is the first immuno-oncology combination treatment to demonstrate long-term clinical benefit for advanced melanoma patients. We evaluated the cost effectiveness of the Regimen in this population, with and without the availability of overall surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, D., Amadi, A., Sabater, J., Ellis, J., Johnson, H., Kotapati, S., McNamara, S., Walker, A., Cooper, M., Patterson, K., Roskell, N., Meng, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393277/
https://www.ncbi.nlm.nih.gov/pubmed/29790020
http://dx.doi.org/10.1007/s41669-018-0080-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393277/
https://www.ncbi.nlm.nih.gov/pubmed/29790020
http://dx.doi.org/10.1007/s41669-018-0080-5

Ejemplares similares